export const boardMembers = [
  {
    name: "Rita Dobmeyer",
    role: "Board Member",
    image:
      "https://cdn.builder.io/api/v1/image/assets/TEMP/1173aecc3998150539070dc98bdb6300ce6e58dbcea40c2c11f03550818cfeae?placeholderIfAbsent=true&apiKey=2b44f754f55f493a80610f16cd61c8e9",
    description:
      "Rita Dobmeyer is the CEO of the European CRO Galenus G&H AG. Prior to this she was Director of European Consulting and Client Relations for Parexel GmbH, and Director of Phase IV Clinical Services and Post-Marketing Surveillance at IMS Health. Rita is the founder of eight companies and has networks with investors and key opinion leaders around the world. She is a graduate of the University of Kaiserslautern, with a PhD in infection from the German Cancer Research Centre, Heidelberg.",
  },
  {
    name: "Arnold Wong",
    role: "Board Member",
    image:
      "https://cdn.builder.io/api/v1/image/assets/TEMP/d8b7a58422674235370b26eb171a726b34c080d8f46a37afab069ebda7a66982?placeholderIfAbsent=true&apiKey=2b44f754f55f493a80610f16cd61c8e9",
    description: `Cofounder of multi-national CRO Inclin, has hands-
on experience in pre-clinical pharmacology drug
development and extensive experience in clinical
project management. He brings over thirty years of
experience to an organization recognized for its
commitment to quality, clinical experience and high
employee retention. He began his career as a
research scientist at Cardima, Inc., COR
Therapeutics, and Syntex Research.`,
  },
  {
    name: "Marc Shirman",
    role: "Board Director",
    image:
      "https://cdn.builder.io/api/v1/image/assets/TEMP/023b3e3cef5e8b0c0451dee3a6dc4d0c22834c7e6530d1f8c67e8bd219a8f239?placeholderIfAbsent=true&apiKey=2b44f754f55f493a80610f16cd61c8e9",
    description: `Marc Shirman joined the board in 2023 to manage
the bridge capital investment in Blueberry.
Following the acquisition by Sanoderm, Marc is
responsible for commercialising the assets of the
business. He is formerly the Co-Head of UK Private
Capital at Muzinich & Co and previously Head of
Financial Sponsors at NatWest Markets.`,
  },
];

export const advisors = [
  {
    name: "A Ray Chaudhuri",
    role: "Executive Chair",
    description:
      "Bob Clay is a pharmacist with more than 30 years of experience in drug development, leading the global regulatory approval of many products across a range of therapy areas, including more than 15 new active substances. Previously, he was VP of Global Regulatory Affairs at AstraZeneca with responsibility for oncology, infection and personalised healthcare. Bob is a Fellow and Board Member at TOPRA (President in 2017) and a member of the Expert Scientific Advisory Committee for Medicines for Malaria Venture. Bob has held significant leadership roles in regulatory affairs in regional and global functions at Pfizer, AstraZeneca and Kinapse.",
  },
  {
    name: "Friedrich K. Mayer",
    role: "Advisor to the board",
    description:
      "Friedrich K. Mayer has ~50 years' experience in the pharmaceutical industry, both in drugs and vaccines. Starting in the Sandoz Research Institute, later Novartis, he took six NMEs from research through registration to life cycle management. These include terbinafine (Lamisil®), the gold standard for the treatment of onychomycosis, and the first allylamine antifungal, naftifine (Exoderil®/Naftin®). Since then, Friedrich worked with various biotechnology firms. He has extensive experience in the areas of dermatology and infectious diseases and holds a Dr.Sc. (chemistry) from the University of Technology in Vienna, and an MBA from INSEAD in Fontainebleau.",
  },
];

export const observers = [];
